Industry News
Pharmaceutical Industry News
Trump Announces Proposals to Make I.V.F. More Affordable
The president unveiled several policy proposals on Thursday aimed at reducing the costs of in vitro fertilization. They included a deal with a pharmaceutical company to lower drug costs, and guidance encouraging employers to offer
In the first opportunity for…
In the first opportunity for industry watchers to compare the two approved TROP2 antibody-drug conjugates side by side in separate global phase 3 trials in the same disease setting, it’s AstraZeneca and Daiichi Sankyo’s Datroway
Results presented by AstraZeneca…
Results presented by AstraZeneca from its phase 3 trial of Imfinzi in patients with high-risk, non-muscle invasive bladder cancer (NMIBC) suggest that the PD-L1 inhibitor measures up to Pfizer’s PD-1 candidate sasanlimab.
Dianthus and Boehringer Ingelheim…
Dianthus and Boehringer Ingelheim headlined the latest round of licensing deals featuring China biotechs. Fierce's deep dive into the dispute between Novo Nordisk and KBP Biosciences wrapped up with Chapter 3. Takeda inked its second
With the launch of its first…
With the launch of its first direct-to-patient program, Genentech is joining the wave of drugmakers setting up direct-to-consumer sales of popular products at steep discounts for cash-paying patients.
The standing ovation for Keytruda…
The standing ovation for Keytruda and Padcev in metastatic bladder cancer at ESMO 2023 still echoes, and, now, the pair from Merck & Co., Pfizer and Astellas has pulled off similarly showstopping results in certain
A Keytruda-based regimen has shown…
A Keytruda-based regimen has shown a statistically significant overall survival benefit in all comers with platinum-resistant recurrent ovarian cancer regardless of their PD-L1 expression levels.
At the final analysis of the phase…
At the final analysis of the phase 3 Applause-IgAN trial, Novartis’ complement factor B inhibitor Fabhalta showed that it can slow kidney function decline and IgAN progression, the company said. Novartis plans to leverage the
Eli Lilly hopes its latest overall…
Eli Lilly hopes its latest overall survival win could increase the adoption of Verzenio and, by extension, the entire CDK4/6 inhibitor class in early breast cancer.
A well-established diabetes drug…
A well-established diabetes drug alleviated brain inflammation in a female mouse model of multiple sclerosis, suggesting the long-used medicine could be repurposed to combat MS in people with female sex chromosomes, who are disproportionately affected
America Is Heavily Reliant on China for Raw Materials in Medicines
A new analysis found that nearly 700 drugs approved for use in the United States depend on chemicals solely produced in China.
Veradermics will use the funding…
Veradermics will use the funding to support further phase 3 development for its extended-release formulation of oral minoxidil, a decades-old hypertension treatment that's commonly used off-label for hair loss.
Following a strong early showing…
Following a strong early showing of Tecvayli and Darzalex Faspro in newly diagnosed multiple myeloma patients last month, Johnson & Johnson is making the case for its oncology cocktail as a potential second-line therapy for
In separate announcements on…
In separate announcements on Wednesday, a pair of agencies shared business updates both aimed at leveling up their respective abilities to connect with doctors and patients—as standard healthcare marketing practices are being upended by AI
With sales of potential…
With sales of potential blockbuster Lokelma scaling up, AstraZeneca is bolstering its production of the hyperkalemia treatment with a $445 million injection of funds. The investment will increase the capabilities of AZ’s manufacturing facility in
Through the agreement, Scynexis…
Through the agreement, Scynexis will oblige GSK's request to wind down its phase 3 study of antifungal med Brexafemme in invasive candidiasis, which it had restarted after the FDA lifted a clinical hold earlier this
In addition to substantial spray…
In addition to substantial spray drying capacity, new CDMO Codis says it's also equipped to handle commercial-scale work on amorphous solid dispersions, particle engineering and finished dose manufacturing for pharma, consumer health and over-the- counter
GSK’s study evaluated the…
GSK's study evaluated the tolerability and acceptability of its long-acting pre-exposure prophylaxis drug Apretude compared with Gilead's rival Yeztugo.
After Rezdiffra’s approval and…
After Rezdiffra’s approval and Wegovy’s label expansion, the race is on in metabolic dysfunction-associated steatohepatitis. M&A deals totaling more than $10 billion in recent months show major pharma players still see sizable opportunity in the
Just a few months after surfacing…
Just a few months after surfacing at Orca Bio following his early 2025 departure from Legend Biotech, Steve Gavel has taken on the chief commercial officer role at yet another cell therapy biotech.